Effect of p53β on human gastric cancer cells treated with recombinant mutated human TNF and cisplatin

Ji,Wansheng; Yuan,Mingliang; Zhang,Li; Zhang,Hongmei; Jiao,Jianxin; Gao,Zhixing

doi:10.3892/mmr.2017.6436

Effect of p53β on human gastric cancer cells treated with recombinant mutated human TNF and cisplatin

Authors:
- Wansheng Ji
- Mingliang Yuan
- Li Zhang
- Hongmei Zhang
- Jianxin Jiao
- Zhixing Gao
View Affiliations

Affiliations: Department of Gastroenterology, The Affiliated Hospital of Weifang Medical University, Weifang, Shandong 261031, P.R. China, Department of Gastroenterology, Graduate School of Weifang Medical University, Weifang, Shandong 261031, P.R. China
Published online on: April 4, 2017 https://doi.org/10.3892/mmr.2017.6436
Pages: 3865-3870

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the role of tumour protein 53 isoform b (p53β) on human gastric cancer (GC) cell lines treated with recombinant mutated human tumour necrosis factor (rmhTNF) and cisplatin. The Cell Counting Kit‑8 assay was used to assess growth in the GC cell lines MKN45 and SGC7901, following treatment with rmhTNF in the presence or absence of cisplatin. Levels of p53β and bcl‑2 apoptosis regulator (bcl‑2) mRNA were assessed using reverse transcription‑polymerase chain reaction. The results demonstrated that growth was significantly inhibited by either cisplatin or rmhTNF treatments alone in MKN45 cells, and combination treatment with cisplatin and rmhTNF had a synergistic effect on growth inhibition of MKN45 cells. Notably, these observations were not evident in SGC7901 cells, where a mutant form of p53 is present. Treatment of MKN45 cells with rmhTNF did not affect bcl‑2 or p53β mRNA expression levels. However, treatment of MKN45 cells with cisplatin induced upregulation of p53β and downregulation of bcl-2 mRNA expression levels, and these effects were enhanced by combination treatment with rmhTNF. Pearson correlation analysis revealed a negative correlation between the expression of p53β and bcl‑2 mRNA, and a negative correlation between bcl-2 mRNA expression and the inhibition of cell growth. In conclusion, the inhibitory effect of cisplatin on the growth of MKN45 GC cells was enhanced by rmhTNF via unknown mechanisms that involved p53β, indicating that p53β may be an appropriate therapeutic target for the treatment of GC.

View Figures

View References

1	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
3	Schirren R, Reim D and Novotny AR: Adjuvant and/or neoadjuvant therapy for gastric cancer cancer? A perspective review. Ther Adv Med Oncol. 7:39–48. 2015. View Article : Google Scholar : PubMed/NCBI
4	Ito S, Oki E, Nakashima Y, Ando K, Hiyoshi Y, Ohgaki K, Saeki H, Morita M, Sakaguchi Y and Maehara Y: Clinical significance of adjuvant surgery following chemotherapy for patients with initially unresectable stage IV gastric cancer. Anticancer Res. 35:401–406. 2015.PubMed/NCBI
5	Lane DP and Crawford LV: T antigen is bound to a host protein in SV40-transformed cells. Nature. 278:261–263. 1979. View Article : Google Scholar : PubMed/NCBI
6	Stegh AH: Targeting the p53 signaling pathway in cancer therapy-the promises, challenges and perils. Expert Opin Ther Targets. 16:67–83. 2012. View Article : Google Scholar : PubMed/NCBI
7	Busuttil RA, Zapparoli GV, Haupt S, Fennell C, Wong SQ, Pang JM, Takeno EA, Mitchell C, Di Costanzo N, Fox S, et al: Role of p53 in the progression of gastric cancer. Oncotarget. 5:12016–12026. 2014. View Article : Google Scholar : PubMed/NCBI
8	Yoshimura A, Sugihara H, Ling ZQ, Peng DF, Mukaisho K, Fujiyama Y and Hattori T: How wild-type TP53 is inactivated in undifferentiated-type gastric carcinomas: Analyses of intratumoral heterogeneity in deletion and mutation of TP53. Pathobiology. 73:40–49. 2006. View Article : Google Scholar : PubMed/NCBI
9	Chan WM and Poon RY: The p53 Isoform Deltap53 lacks intrinsic transcriptional activity and reveals the critical role of nuclear import in dominant-negative activity. Cancer Res. 67:1959–1969. 2007. View Article : Google Scholar : PubMed/NCBI
10	Courtois S, Verhaegh G, North S, Luciani MG, Lassus P, Hibner U, Oren M and Hainaut P: DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene. 21:6722–6728. 2002. View Article : Google Scholar : PubMed/NCBI
11	Marcel V, Perrier S, Aoubala M, Ageorges S, Groves MJ, Diot A, Fernandes K, Tauro S and Bourdon JC: Δ160p53 is a novel N-terminal p53 isoform encoded by Δ133p53 transcript. FEBS Lett. 584:4463–4468. 2010. View Article : Google Scholar : PubMed/NCBI
12	Chambers SK and Martinez JD: The significance of p53 isoform expression in serous ovarian cancer. Future Oncol. 8:683–686. 2012. View Article : Google Scholar : PubMed/NCBI
13	Philipova T, Baryawno N, Hartmann W, Pietsch T, Druid H, Johnsen JI and Ekström TJ: Differential forms of p53 in medulloblastoma primary tumors, cell lines and xenografts. Int J Oncol. 38:843–849. 2011.PubMed/NCBI
14	Goldschneider D, Horvilleur E, Plassa LF, Guillaud-Bataille M, Million K, Wittmer-Dupret E, Danglot G, de Thé H, Bénard J, May E and Douc-Rasy S: Expression of C-terminal deleted p53 isoforms in neuroblastoma. Nucleic Acids Res. 34:5603–5612. 2006. View Article : Google Scholar : PubMed/NCBI
15	Wei J, Noto J, Zaika E, Romero-Gallo J, Correa P, El-Rifai W, Peek RM and Zaika A: Pathogenic bacterium Helicobacter pylori alters the expression profile of p53 protein isoformsand p53 response to cellular stresses. Proc Natl Acad Sci USA. 109:pp. E2543–E2550. 2012; View Article : Google Scholar : PubMed/NCBI
16	Wei J, O'Brien D, Vilgelm A, Piazuelo MB, Correa P, Washington MK, El-Rifai W, Peek RM and Zaika A: Interaction of Helicobacter pylori with gastric epithelial cells is mediated by the p53 protein family. Gastroenterology. 134:1412–1423. 2008. View Article : Google Scholar : PubMed/NCBI
17	Roberts NJ, Zhou S, Diaz LA Jr and Holdhoff M: Systemic use of tumor necrosis factor alpha as an anticancer agent. Oncotarget. 2:739–751. 2011. View Article : Google Scholar : PubMed/NCBI
18	Jiang C, Niu J, Li M, Teng Y, Wang H and Zhang Y: Tumor vasculature-targeted recombinant mutated human TNF-α enhanced the antitumor activity of doxorubicin by increasing tumor vessel permeability in mouse xenograft models. PLoS One. 9:e870362014. View Article : Google Scholar : PubMed/NCBI
19	Li M, Xu T, Zhang Z, Xue X, Zhang C, Qin X, Li W, Hao Q, Zhang W and Zhang Y: Phase II multicenter, randomized, double-blind study of recombinant mutated human tumor necrosis factor-α in combination with chemotherapies in cancer patients. Cancer Sci. 103:288–295. 2012. View Article : Google Scholar : PubMed/NCBI
20	Kafshdooz T, Tabrizi AD, Ardabili SM Mohaddes, Kafshdooz L, Ghojazadeh M, Gharesouran J, Abdii A and Alizadeh H: Polymorphism of p53 gene codon 72 in endometrial cancer: Correlation with tumor grade and histological type. Asian Pac J Cancer Prev. 15:9603–9606. 2014. View Article : Google Scholar : PubMed/NCBI
21	Xu J, Dong H, Shen W, He S, Li H, Lu Y, Wu ZS and Jia L: New molecular beacon for p53 gene point mutation and significant potential in serving as the polymerization primer. Biosens Bioelectron. 66:504–511. 2015. View Article : Google Scholar : PubMed/NCBI
22	Nason KS: Predicting response to neoadjuvant therapy in esophageal cancer with p53 genotyping: A fortune-teller's crystal ball or a viable prognostic tool? J Thorac Cardiovasc Surg. 148:2286–2287. 2014. View Article : Google Scholar : PubMed/NCBI
23	Ji W, Zhang N, Zhang H, Ma J, Zhong H, Jiao J and Gao Z: Expression of p53β and Δ133p53 isoforms in different gastric tissues. Int J Clin Exp Pathol. 8:10468–10474. 2015.PubMed/NCBI
24	Marcel V, Fernandes K, Terrier O, Lane DP and Bourdon JC: Modulation of p53β and p53γ expression by regulating the alternative splicing of TP53 gene modifies cellular response. Cell Death Differ. 21:1377–1387. 2014. View Article : Google Scholar : PubMed/NCBI
25	Avery-Kiejda KA, Morten B, Wong-Brown MW, Mathe A and Scott RJ: The relative mRNA expression of p53 isoforms in breast cancer is associated with clinical features and outcome. Carcinogenesis. 35:586–596. 2014. View Article : Google Scholar : PubMed/NCBI
26	Hofstetter G, Berger A, Fiegl H, Slade N, Zorić A, Holzer B, Schuster E, Mobus VJ, Reimer D, Daxenbichler G, et al: Alternative splicing of p53 and p73: The novel p53 splice variant p53delta is an independent prognostic marker in ovarian cancer. Oncogene. 29:1997–2004. 2010. View Article : Google Scholar : PubMed/NCBI
27	Hofstetter G, Berger A, Berger R, Zorić A, Braicu EI, Reimer D, Fiegl H, Marth C, Zeimet AG, Ulmer H, et al: The N-terminally truncated p53 isoform Δ40p53 influences prognosis in mucinous ovarian cancer. Int J Gynecol Cancer. 22:372–379. 2012. View Article : Google Scholar : PubMed/NCBI
28	Hofstetter G, Berger A, Schuster E, Wolf A, Hager G, Vergote I, Cadron I, Sehouli J, Braicu EI, Mahner S, et al: Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer. Br J Cancer. 105:1593–1599. 2011. View Article : Google Scholar : PubMed/NCBI
29	Berglind H, Pawitan Y, Kato S, Ishioka C and Soussi T: Analysis of p53 mutation status in human cancer cell lines: A paradigm for cell line cross-contamination. Cancer Biol Ther. 7:699–708. 2008. View Article : Google Scholar : PubMed/NCBI
30	Ji W, Ma J, Zhang H, Zhong H, Li L, Ding N, Jiao J and Gao Z: Role of p53β in the inhibition of proliferation of gastric cancer cells expressing wild-type or mutated p53. Mol Med Rep. 12:691–695. 2015.PubMed/NCBI
31	Zheng S, Zhao M, Ren Y, Wu Y and Yang J: Sesamin suppresses STZ induced INS-1 cell apoptosis through inhibition of NF-κB activation and regulation of Bcl-2 family protein expression. Eur J Pharmacol. 750:52–58. 2015. View Article : Google Scholar : PubMed/NCBI
32	Cekanova M, Fernando RI, Siriwardhana N, Sukhthankar M, De la Parra C, Woraratphoka J, Malone C, Ström A, Baek SJ, Wade PA, et al: BCL-2 family protein, BAD is down-regulated in breast cancer and inhibits cell invasion. Exp Cell Res. 331:1–102. 2015. View Article : Google Scholar : PubMed/NCBI
33	Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP, Saville MK and Lane DP: p53 isoforms can regulate p53 transcriptional activity. Genes Dev. 19:2122–2137. 2005. View Article : Google Scholar : PubMed/NCBI
34	Khoury MP and Bourdon JC: p53 isoforms: An intracellular microprocessor? Genes Cancer. 2:453–465. 2011. View Article : Google Scholar : PubMed/NCBI
35	Silden E, Hjelle SM, Wergeland L, Sulen A, Andresen V, Bourdon JC, Micklem DR, McCormack E and Gjertsen BT: Expression of TP53 isoforms p53β or p53γ enhances chemosensitivity in TP53 (null) cell lines. PLoS One. 8:e562762013. View Article : Google Scholar : PubMed/NCBI
36	Okumura N, Yoshida H, Kitagishi Y, Nishimura Y and Matsuda S: Alternative splicings on p53, BRCA1 and PTEN genes involved in breast cancer. Biochem Biophys Res Commun. 413:395–399. 2011. View Article : Google Scholar : PubMed/NCBI
37	Marcel V, Dichtel-Danjoy ML, Sagne C, Hafsi H, Ma D, Ortiz-Cuaran S, Olivier M, Hall J, Mollereau B, Hainaut P and Bourdon JC: Biological functions of p53 isoforms through evolution: Lessons from animal and cellular models. Cell Death Differ. 18:1815–1824. 2011. View Article : Google Scholar : PubMed/NCBI
38	Cheng P, Shi RH, Zhang HJ, Yu LZ, Zhang GX and Hao B: Effects of tumor necrosis factor-alpha inducing protein-alpha secreted by Helicobacter pylori on human gastric epithelial cells. Zhonghua Yi Xue Za Zhi. 88:1528–1532. 2008.(In Chinese). PubMed/NCBI
39	Fukui T, Matsui K, Kato H, Takao H, Sugiyama Y, Kunieda K and Saji S: Significance of apoptosis induced by tumor necrosis factor-alpha and/or interferon-gamma against human gastric cancer cell lines and the role of the p53 gene. Surg Today. 33:847–853. 2003. View Article : Google Scholar : PubMed/NCBI
40	Shimoyama S, Mochizuki Y, Kusada O and Kaminishi M: Supra-additive antitumor activity of 5FU with tumor necrosis factor-related apoptosis-inducing ligand on gastric and colon cancers in vitro. Int J Oncol. 21:643–648. 2002.PubMed/NCBI